Zepbound Compassionate Use and Expanded Access: What Women Need to Know in 2026

What "Compassionate Use" and "Expanded Access" Actually Mean

Compassionate use is not a discount program. It is an FDA regulatory pathway that allows a patient with a serious or life-threatening condition to receive an investigational or unapproved drug outside of a clinical trial when no comparable alternative exists. Expanded access is the broader legal term that covers individual patient access, intermediate-size groups, and large-scale emergency protocols.

Zepbound received full FDA approval for chronic weight management in August 2023. Because it is already approved, a standard individual compassionate use application for weight management does not apply. The FDA reserves expanded access for drugs that are not yet approved, or for approved drugs being used in a population or indication that is still investigational.

Why This Matters for Women Specifically

Many women searching "Zepbound compassionate use" are actually looking for a way to afford the drug, not for a literal investigational access pathway. That distinction matters enormously because it changes the strategy entirely. The sections below address both the narrow regulatory question and the broader access question that most women are really asking.

Is There an Active Zepbound Expanded Access Program?

As of early 2026, Eli Lilly has not posted an open individual patient expanded access program for tirzepatide on ClinicalTrials.gov for general obesity or weight management. The FDA expanded access database does not list an active Zepbound IND (investigational new drug) program open to individual applications in this indication.

When Expanded Access Might Theoretically Apply

A clinician could submit a single-patient emergency IND request to the FDA if a woman has a life-threatening condition, no comparable alternative, and is not eligible for any trial. In practice, for a drug already approved for obesity, the FDA is unlikely to approve such a request unless the patient has a rare metabolic disorder and a compelling clinical rationale.

Investigational Use in Unapproved Indications

Tirzepatide is currently being studied in several conditions that affect women at higher rates. The SURMOUNT-5 trial compared tirzepatide directly against semaglutide. Separate investigator-initiated work is ongoing in PCOS-related insulin resistance and perimenopausal metabolic syndrome. Enrollment in an active trial is the legitimate route to receiving tirzepatide at no cost when the indication is still investigational. ClinicalTrials.gov is the right place to search; filter by "tirzepatide" and your specific condition.

Who Zepbound Is FDA-Approved For (and Where the Evidence Is Weakest in Women)

FDA labeling approves Zepbound for adults with a BMI ≥30, or BMI ≥27 with at least one weight-related condition such as type 2 diabetes, hypertension, dyslipidemia, obstructive sleep apnea, or cardiovascular disease.

The key SURMOUNT-1 trial enrolled 2,539 adults and showed that participants receiving tirzepatide 15 mg lost a mean of 20.9% of body weight over 72 weeks, versus 3.1% with placebo. Women made up the majority of enrollees in SURMOUNT-1 (about 67%), which is an unusually high female representation for an obesity trial.

A Life-Stage Framework for Zepbound Eligibility

Understanding where you sit in your hormonal life changes how weight physiology works and what the evidence looks like for you specifically.

Reproductive years (roughly ages 18 to 40). Insulin resistance and androgen excess from PCOS are common drivers of weight gain in this group. Tirzepatide improves insulin sensitivity through its dual GIP/GLP-1 receptor agonism, which is mechanistically relevant to PCOS. A 2024 pilot study published in Fertility and Sterility found that GLP-1 receptor agonists reduced androgen levels and improved menstrual regularity in women with PCOS and obesity, though tirzepatide-specific PCOS data in humans remains limited. Be honest with yourself and your prescriber about this gap: what we know about tirzepatide in PCOS is largely extrapolated from GLP-1 class data, not from dedicated tirzepatide-PCOS trials.

Trying to conceive. Zepbound is contraindicated in pregnancy and must be stopped before conception attempts. See the dedicated pregnancy section below.

Perimenopause (typically ages 45 to 55). Declining estrogen shifts fat distribution toward visceral adiposity and worsens insulin resistance. Small studies suggest GLP-1 receptor agonists may be particularly effective in postmenopausal women because of this metabolic phenotype, but large head-to-head data stratified by menopausal status do not yet exist. The Menopause Society has not yet issued a specific position statement on GLP-1 agonists in menopause management, though a clinical guidance document is expected.

Post-menopause. Bone loss is a concern. Animal data suggest GLP-1 receptor agonism may have modest bone-protective effects, but the clinical significance in post-menopausal women on Zepbound is unknown. Monitoring bone density with DXA scanning every 2 years remains standard for women at risk for osteoporosis regardless of GLP-1 use, per ACOG guidance on osteoporosis prevention.

Pregnancy, Lactation, and Contraception: Non-Negotiable Details

Zepbound is contraindicated in pregnancy. The FDA label carries explicit language: animal studies demonstrated fetal harm at doses relevant to human exposure, and there are no adequate human pregnancy data. The prescribing information states that Zepbound should be discontinued at least 2 months before a planned pregnancy because of the drug's long washout period.

Unintended pregnancy is a real risk. GLP-1 receptor agonists may reduce the systemic absorption of oral contraceptives by slowing gastric emptying. ACOG recommends that women taking GLP-1 agonists who rely on oral contraceptive pills consider a backup contraceptive method or switch to a non-oral method such as an IUD or implant.

Lactation

Tirzepatide transfer into human breast milk has not been studied. The FDA label states that the drug is present in rat milk but acknowledges no human data. Given the absence of safety data and the potential for drug transfer affecting a nursing infant, most clinicians advise against using Zepbound while breastfeeding. If postpartum weight management is a priority, discuss timing and alternatives with your provider. The postpartum period is already a time of significant hormonal flux, and GLP-1 agonists can suppress appetite in ways that may compromise milk supply, though direct evidence on lactation quantity in humans is not available.

Contraception Requirements

• If you are of reproductive age and sexually active, use reliable, non-oral contraception or a combined method while on Zepbound.
• Stop Zepbound at least 2 months before any planned conception attempt.
• If you discover you are pregnant while taking Zepbound, stop immediately and contact your OB-GYN. Report the exposure to the Zepbound pregnancy registry or through your prescriber.

The Real Access Routes: What Actually Works in 2026

Because a formal compassionate use program does not exist for Zepbound, here are the concrete pathways women are using to manage cost.

1. Lilly Savings Card for Commercially Insured Patients

Eli Lilly offers a savings card through LillyDirect that caps monthly co-pay at approximately $25 for eligible commercially insured patients, subject to program terms that Lilly can change. Government insurance programs (Medicare, Medicaid, TRICARE) are not eligible. The savings card is not income-based; it requires that you have commercial insurance that covers Zepbound, even partially.

2. LillyDirect Single-Dose Vials (Cash-Pay Option)

In late 2023, Lilly launched a direct-to-consumer vial option through LillyDirect that offers tirzepatide vials at a substantially lower cash price than the branded auto-injector pens. As of early 2026, vials are available in lower doses (2.5 mg and 5 mg) at prices roughly 50% below the auto-injector list price, though exact pricing changes frequently. The vials require a valid prescription and are shipped to your home through a partner pharmacy. This is the most concrete cost-reduction option for uninsured women or those with non-covering insurance.

3. Clinical Trials

Enrollment in an NIH-registered clinical trial is the one legitimate way to receive tirzepatide at no cost outside normal prescribing channels. Active trials as of early 2026 include studies in PCOS, heart failure, non-alcoholic steatohepatitis (NASH), and sleep apnea. Women with these conditions who meet enrollment criteria may qualify. Search ClinicalTrials.gov with the terms "tirzepatide" and your specific condition; contact the trial coordinator directly.

4. HSA and FSA Funds

Zepbound prescribed for an FDA-approved indication (obesity with BMI ≥30, or BMI ≥27 with a qualifying condition) qualifies as a reimbursable expense under a Health Savings Account (HSA) or Flexible Spending Account (FSA). IRS Publication 502 defines qualified medical expenses to include prescription drugs, and the Affordable Care Act's preventive services rules now classify obesity counseling as a covered preventive service, which has expanded insurer coverage in some plans. Concretely: if you pay for Zepbound out of pocket, you can use pre-tax HSA or FSA dollars, effectively reducing your real cost by your marginal tax rate. For a woman in the 22% federal bracket, a $500 monthly cost becomes approximately $390 in after-tax terms. Keep your prescription receipt and Explanation of Benefits.

5. Manufacturer Patient Assistance Programs

Lilly's Lilly Cares Foundation provides free medication to uninsured or underinsured patients who meet income criteria (typically household income at or below 400% of the federal poverty level). Applications require income documentation and a prescription. Processing takes several weeks, and supply is not guaranteed. This is a distinct program from the savings card.

6. Insurance Prior Authorization Strategy

Many commercial plans require prior authorization for Zepbound and may deny a first request. A successful appeal typically includes documentation of a qualifying BMI, a qualifying comorbidity, and prior treatment with at least one other anti-obesity agent (often orlistat or phentermine-topiramate). Your prescriber's office should submit a PA on your behalf. If denied, you have the right to request an internal appeal and then an external independent review under the ACA appeals process. Women with PCOS, sleep apnea, or hypertension are often in a stronger position for PA approval because of the documented comorbidity.

Who This Drug Is Right For and Who Should Pause

Life-Stage Fit

Women who tend to be the clearest candidates for Zepbound include those in the reproductive years or perimenopause with a BMI meeting label criteria, PCOS with insulin resistance that has not responded to metformin, and post-menopausal women with metabolic syndrome and cardiovascular risk who are not pregnant or breastfeeding.

Women who should wait or choose an alternative:

• Anyone actively trying to conceive, pregnant, or breastfeeding
• Women with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia type 2 (MEN2), both of which are listed contraindications
• Women with a history of pancreatitis (use with caution, not an absolute contraindication, but risk-benefit discussion required)
• Women with severe gastroparesis, since tirzepatide slows gastric emptying significantly

PCOS-Specific Note

The evidence gap here deserves candor. We do not yet have a randomized controlled trial of tirzepatide in PCOS that was powered for reproductive or hormonal outcomes. The SURMOUNT program did not pre-specify PCOS as a subgroup. Mechanistically, tirzepatide's GIP receptor agonism adds a dimension not present in GLP-1-only drugs, and GIP receptors are expressed in ovarian tissue, but whether this translates into better menstrual regulation or fertility outcomes for women with PCOS than semaglutide would provide is genuinely unknown. Ask your prescriber to be explicit about what is established versus what is plausible inference.

Tirzepatide and Menstrual Cycle Changes

Women on GLP-1 receptor agonists, including tirzepatide, report menstrual changes that are not fully characterized in the trial literature. Rapid weight loss can temporarily disrupt the hypothalamic-pituitary-ovarian axis, leading to irregular cycles or missed periods. This is a known consequence of significant caloric restriction and weight loss rather than a direct pharmacologic effect of tirzepatide itself. A 5-10% reduction in body weight in women with PCOS frequently restores ovulation, which can increase fertility even if a woman has been previously anovulatory. That unexpected return of fertility is exactly why reliable contraception is non-negotiable while on Zepbound.

Women who notice significant menstrual irregularity beyond the first 2-3 months of use, or who experience amenorrhea for more than 3 consecutive cycles, should be evaluated for thyroid dysfunction, hyperprolactinemia, and hypothalamic amenorrhea, as these are common coinciding diagnoses. ACOG's guidance on abnormal uterine bleeding provides a structured approach to workup.

Sex-Specific Pharmacokinetics: Do Women Need Different Doses?

The prescribing information does not recommend sex-based dose adjustments for tirzepatide. Body weight is the primary driver of volume of distribution, and dosing is fixed regardless of sex. A population pharmacokinetic analysis from the SURMOUNT program found that women had approximately 14-18% higher area-under-the-curve (AUC) tirzepatide exposure than men at the same dose, attributable largely to lower mean body weight and differences in body composition. This analysis was published in Clinical Pharmacokinetics and suggests that women may reach therapeutic exposure at the lower end of the dose range more readily than men, though the clinical significance is modest and titration should still be driven by tolerability and response.

Nausea and vomiting are the most common adverse effects and are reported at higher rates in women in GLP-1 agonist trials generally. Slow titration (staying at 2.5 mg for at least 4 weeks before escalating) reduces GI side effects meaningfully. Eating smaller portions, avoiding high-fat meals, and not lying down for 2-3 hours after eating are practical steps to reduce nausea that work particularly well for women, who have slower baseline gastric emptying than men on average.

How Programs Change and What to Watch

Access programs for GLP-1 agonists have shifted rapidly since 2023. The FDA shortage designation for tirzepatide was removed in late 2024, which ended the period when compounded tirzepatide was more broadly available. Compounded tirzepatide from 503A or 503B pharmacies is no longer FDA-sanctioned now that the branded product shortage has been resolved; the FDA's compounding guidance makes clear that compounding of essentially a copy of an approved drug is not permitted once the shortage designation is lifted.

Lilly's pricing and savings card terms have changed at least twice since Zepbound launched. Bookmark the LillyDirect Zepbound page and the Lilly Cares Foundation page for current numbers rather than relying on articles published more than 6 months ago, including this one if you are reading it in late 2026 or beyond.